U.S. markets closed
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • Dow 30

    34,777.76
    +229.26 (+0.66%)
     
  • Nasdaq

    13,752.24
    +119.44 (+0.88%)
     
  • Russell 2000

    2,271.63
    +30.21 (+1.35%)
     
  • Crude Oil

    64.82
    +0.11 (+0.17%)
     
  • Gold

    1,832.00
    +16.30 (+0.90%)
     
  • Silver

    27.57
    +0.09 (+0.32%)
     
  • EUR/USD

    1.2167
    +0.0098 (+0.82%)
     
  • 10-Yr Bond

    1.5770
    +0.0160 (+1.02%)
     
  • GBP/USD

    1.3990
    +0.0098 (+0.70%)
     
  • USD/JPY

    108.5400
    -0.5450 (-0.50%)
     
  • BTC-USD

    57,420.18
    -1,568.13 (-2.66%)
     
  • CMC Crypto 200

    1,480.07
    +44.29 (+3.08%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,357.82
    +26.42 (+0.09%)
     

Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has opened the investigational new drug application for Phase 3 trial for Akari Therapeutics Plc's (NASDAQ: AKTX) lead drug candidate, nomacopan, for the treatment of moderate and severe Bullous Pemphigoid (BP), allowing clinical sites to open mid-2021, subject to the ongoing impact of COVID related restrictions.

  • Akari has been granted orphan drug designation for nomacopan to treat BP by both the FDA and the European Medicines Agency (EMA).

  • BP is a rare skin condition that causes large, fluid-filled blisters. They develop on skin areas that often flex, such as the lower abdomen, upper thighs, or armpits.

  • In patients with BP, there is evidence that nomacopan's ability to inhibit C5 and LTB4 gives it a unique potential therapeutic advantage which is upstream of other approaches (such as cytokine inhibitors) that are being investigated for the treatment of BP.

  • Nomacopan (formerly known as Coversin) is a C5 complement inhibitor that independently and specifically binds to and inhibits leukotriene B4 (LTB4) activity.

  • Akari's pivotal Phase 3 trial design is a randomized placebo-controlled study with nomacopan in patients with moderate to severe BP with a primary endpoint of disease remission on minimal oral corticosteroids.

  • Price Action: AKTX shares are down 10.4% at $2.16 in market trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.